Teva Germany (GmbH) presented at the DGN Congress 2021 the first interim analysis results of the FINESSE study aiming to provide real-world evidence of fremanezumab treatment outcomes by evaluating effectiveness in routine clinical practice. 97.6% of patients included in the study had already received preventive migraine therapies in the 10 years prior to study entry, including antidepressants, anticonvulsants, beta-blockers, ca-antagonists, onabotulinumtoxinA as well as other anti-CGRP mAbs. The primary endpoint measure was the proportion of patients reaching = 50% reduction in the monthly average number of migraine days evaluated during the 6-month period after the first dose of fremanezumab. 48.7% of the patients with 6-month data achieved the primary endpoint, with a higher percentage in EM (53.2%) than CM patients (43.0%). Real-world response rates are thus in line with Phase-III-study results of fremanezumab. The mean number of migraine days per month (d/m) decreased from 12.7 (baseline) to 6.2 (month 6). From baseline to month 6, the mean MIDAS Score decreased from 74.8 at baseline to 32.8 and the mean HIT-6 Score from 65.9 at baseline to 56.6. Acute migraine medication use decreased from 9.6 days/month at baseline to 4.4 d/m at month 6.